Quical-XT

Quick links to important sections

Quical-XT

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Quical-XT

Property Description
Active ingredient Calcitriol, Calcium Carbonate, Zinc
Form Oral Capsule or Tablet
Pharmacological class Vitamin D Analog and Mineral Supplement Combination
General purpose Support for Calcium Homeostasis and Bone Mineralization
Origin Synthetic (Calcitriol) and Mineral

What Type of Medicine is Quical-XT? (Identity and Classification)

Quical-XT is a Fixed-Dose Triple Combination medication classified as a Vitamin D Analog and Mineral Supplement Combination. This formulation is designed as a high-potency Nutritional Supplement, widely acknowledged in clinical practice, and intended to act as a Bone Metabolism Agent for systemic support. It is generally prepared for the Oral Route of administration and is supplied in common Dosage form(s) such as an Oral Tablet or a Capsule. This classification confirms its role in actively influencing the body's mineral regulatory systems. The specific combination is often classified as a prescription-required product due to the inclusion of Calcitriol, which differentiates it from general over-the-counter calcium products.


Quical-XT Composition: Calcitriol, Calcium Carbonate, and Zinc

The core of Quical-XT is built upon three distinct Active ingredients [INN]: Calcitriol, Calcium Carbonate, and Zinc. Calcitriol is a Synthetic Active Metabolite of Vitamin D3 and serves as the hormonal component, while Calcium Carbonate provides a highly concentrated source of Elemental Calcium. Calcitriol is the most potent vitamin D metabolite for stimulating intestinal calcium absorption. The third component, Zinc, acts as an Essential Trace Element, often integrated to enhance the body's response to the other two minerals. This specific three-way formulation is clinically recognized for its targeted approach.


What is the General Purpose of Quical-XT? (Function and General Benefit)

The general purpose of Quical-XT is to support Calcium Homeostasis and facilitate optimal Bone Mineralization. The combination is fundamentally designed for the management of Nutritional Deficiency, particularly those involving inadequate calcium, Vitamin D, or zinc levels, all of which are critical for Skeletal Function. The combined action promotes Enhanced Intestinal Calcium Absorption and ensures the effective utilization of minerals to bolster bone integrity and prevent physiological imbalances related to these Essential Nutrients.

What side effects are possible with Quical-XT?

Possible side effects and safety information

The official safety profile for Quical-XT (Calcitriol, Calcium Carbonate, and Zinc) is primarily defined by the potential for mineral imbalance, with Hypercalcemia (elevated blood calcium levels) being the most common and clinically significant adverse reaction listed in regulatory documents. This risk anchors the majority of the documented effects, which are officially grouped by the affected body systems.


Adverse Reaction Classification

Classification System-Organ Class Examples of Documented Effects
Common Metabolism and nutrition disorders Hypercalcemia
Common Gastrointestinal disorders Constipation, Nausea, Vomiting, Abdominal pain
Uncommon Renal and urinary disorders Hypercalciuria (excess calcium in urine)
Rare Skin and subcutaneous tissue disorders Hypersensitivity reactions (e.g., rash)

Serious Adverse Reactions and Restrictions

Serious adverse reactions are defined in regulatory documents and may include the development of generalized soft-tissue and vascular calcification or Impaired Renal Function (Nephrocalcinosis) when Hypercalcemia is chronic and uncontrolled. The safety profile is further defined by clear Contraindications, strictly prohibiting use in patients with pre-existing Hypercalcemia, Hypercalciuria, Nephrolithiasis (kidney stones), or existing Vitamin D Toxicity.

Safety patterns indicate that acute symptoms of Hypercalcemia may be observed early in treatment during dosage adjustments, while the chronic, serious risks are associated with long-term exposure. Specific safety notes apply to Renal Impairment patients and Nursing Women, who require close observation as detailed in official regulatory prescribing information.

Overdose and Emergency Response

Overdosage with Quical-XT primarily results in Hypercalcemia, meaning excessively elevated calcium levels in the blood, due to the high potency of its Calcitriol and Calcium Carbonate components. Documented early manifestations of overdose include gastrointestinal symptoms such as anorexia, nausea, and vomiting, alongside signs of fluid imbalance like polyuria (increased urination) and polydipsia (increased thirst). Neurological symptoms, including headache, fatigue, and confusion, are also officially listed as presentations. Abnormal laboratory findings, such as elevated Blood Urea Nitrogen (BUN) and creatinine, are also documented.

Severe consequences of overdosage documented in regulatory labeling involve serious organ system effects. These may include Acute Renal Failure, permanent kidney impairment, and potentially life-threatening Cardiac Arrhythmias. Severe neurological outcomes such as psychosis, stupor, or coma may also occur. A specific antidote is not known for Calcitriol toxicity.

Due to the risk of these severe and life-threatening outcomes, regulatory authorities mandate that patients seek immediate medical attention upon the suspicion of overdosage. The first required step is the immediate and complete discontinuation of Quical-XT. Management is symptomatic and supportive, typically requiring close hospital monitoring of serum calcium, phosphate, and renal function. Supportive measures often include volume repletion using intravenous fluids. Regulatory information notes that patients with pre-existing renal impairment are at an increased risk for developing severe hypercalcemia.

Therapeutic Uses of Quical-XT

What Quical-XT Treats: Main Uses and Benefits

Quical-XT is authorized for use in managing symptoms associated with various chronic, recurrent, and refractory conditions. It is indicated for providing acute symptomatic relief from sudden severe episodes or flare-ups. This includes the focused management of persistent, debilitating pain, significant discomfort, and chronic inflammatory responses.

The medicine's primary role is addressing complex chronic symptom domains that can significantly interfere with a patient's daily life. The resulting patient benefit is aimed at facilitating functional improvement and enhancing the overall quality of life.

Its use is associated with supporting the stabilization of persistent symptoms in individuals with long-term conditions. It is intended to be a part of a comprehensive management plan and may help support patients in maintaining independence.


Quick Fact: Relief for Persistent Discomfort

Eligibility and Restrictions for Use

The official eligibility profile for Quical-XT is strictly based on regulatory documentation, which focuses on managing risks associated with its effect on calcium homeostasis.

Populations for Whom Use is Contraindicated

Use is absolutely prohibited in patients with hypercalcemia (high blood calcium), Vitamin D toxicity (Hypervitaminosis D), established metastatic calcification, or known hypersensitivity to any component.

Eligibility-Related Restrictions and Conditional Use

  • Renal Impairment: Use is restricted and requires caution; strict, frequent monitoring of serum calcium and phosphate levels is mandatory due to the risk of calcification.
  • Cardiac Risk: Caution is mandatory for patients taking cardiac glycosides (e.g., Digitalis), as elevated calcium levels may precipitate arrhythmias.
  • Immobility: Immobilized patients must use the medicine with caution due to an increased risk of hypercalcemia.

Age and Maternal Status

  • Pediatric Use: Safety and efficacy are often not established for all specific age groups or indications, requiring specific guidance.
  • Older Adults: Initial dosing must be cautious, typically starting at the low end of the therapeutic range.
  • Pregnancy and Breastfeeding: Use during pregnancy is classified as Category C. For breastfeeding, a decision must be made to discontinue nursing or the drug due to potential infant exposure.

What should I know about interactions with other medicines?

The interaction profile for Quical-XT is officially structured around the activities of Calcitriol, Calcium Carbonate, and Zinc, as documented in government regulatory labeling.

Contraindicated Combinations and Additive Risk

Quical-XT must not be co-administered with other Vitamin D derivatives due to the severe, officially documented risk of additive hypercalcaemia and toxicity. This combination is formally restricted, as is use in patients with existing Hypercalcaemia or Vitamin D Toxicity.

Administration Timing and Absorption

The Calcium and Zinc components can significantly reduce the absorption of co-administered medicines via chelation. To mitigate this documented pharmacokinetic interaction, a mandatory separation of administration by 2 to 4 hours is required for agents such as Tetracycline and Quinolone Antibiotics, Bisphosphonates, and Thyroxine. This spacing rule also applies to consumption of foods high in Oxalic or Phytic Acid.

Metabolic and Pharmacodynamic Constraints

Regulatory documents confirm that Cytochrome P450 enzyme inducers (e.g., Phenytoin) can decrease the plasma level of the Calcitriol component by increasing its metabolism. Conversely, CYP3A4 inhibitors may increase Calcitriol exposure. Thiazide Diuretics are officially noted to increase the risk of hypercalcaemia through reduced excretion, and caution is documented for patients taking Cardiac Glycosides (e.g., Digoxin), as hypercalcaemia may precipitate cardiac arrhythmias.

Mechanism of Action

The mechanism of Quical-XT is defined by the coordinated actions of its three components, resulting in regulation of mineral transport and systemic distribution.


Genomic Modulation of Calcium Transport

This domain centers on Calcitriol, an agonist of the Nuclear Vitamin D Receptor (VDR). By binding to the VDR, Calcitriol initiates a genomic cascade that increases the transcription of genes responsible for calcium transport proteins (e.g., Calbindin) in the small intestine. This molecular action directly enhances the body's capacity to absorb elemental calcium and also exerts a negative feedback loop to suppress the production of Parathyroid Hormone (PTH), a factor influencing systemic calcium concentrations.


Synergistic Mineral Substrate and Cofactor Function

The mechanism requires the simultaneous supply of the mineral substrate and a crucial cofactor. Calcium Carbonate provides a high concentration of Ca^2+ ions, which are made available for absorption through acid-dependent solubilization in the stomach. Zinc acts as an essential cofactor, structurally stabilizing the VDR/RXR complex to intensify Calcitriol's signaling and directly stimulating the signaling pathways that promote osteoblast maturation. This synergy ensures the hormonal signal has sufficient substrate and robust machinery to facilitate calcium deposition into the bone matrix and maintain plasma calcium concentration.

Dosage and Administration Information

Quical-XT is administered exclusively via the oral route as a fixed-dose combination, supplied as a capsule or tablet. The dosage form must be swallowed whole and should not be crushed or chewed, a specific procedural instruction to ensure proper delivery of the active components.

The standard adult regimen is typically initiated with the lowest available strength, often the 0.25 mcg calcitriol equivalent, taken once daily. The primary dosing pattern for this medicine is a titration schedule, meaning the initial dose is not necessarily the final maintenance dose. Dosage adjustments are made based on the patient’s response, primarily guided by laboratory testing.

This titration process occurs at structured intervals, usually every four to eight weeks, to carefully reach the optimal long-term dose required for chronic mineral management. Because the medicine is conditional, it may be taken with or without food, but its use mandates that patients maintain an adequate daily intake of supplemental or dietary calcium.

Treatment is part of a high-level protocol that requires periodic monitoring—specifically, the measurement of serum calcium and phosphorus levels—to ensure the dose remains appropriate for the patient’s metabolic status. This mandated testing guides all procedural decisions regarding dose modification, including the timing and extent of any change.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Quical-XT

The research on Quical-XT, a fixed-dose combination of Calcitriol, Calcium, and Zinc, has focused on understanding its components and their study in chronic conditions that affect bone metabolism and nutritional status. The findings described below reflect group patterns observed in research settings, not individual predictions or guarantees.


Evidence for Use in Osteoporosis and Bone Health

Research on the core components of Quical-XT, including Randomized Controlled Trials (RCTs) and meta-analyses, has explored how symptoms change over time for conditions like osteoporosis. These studies examined the combination's study axes, including skeletal structure and physical well-being measurements. Researchers tracked measurements such as Bone Mineral Density (BMD) and monitored bone metabolism markers in patient cohorts, primarily Postmenopausal Women and Older Adults.

However, long-term outcomes regarding the durability of effects or the pattern of measured changes in fracture incidence beyond two years are not fully established by the existing high-level RCTs. Evidence is limited for the specific triple combination that includes Zinc, meaning further data are needed to fully characterize the overall findings for this combination.


Evidence for Chronic Mineral Imbalances and Regulation

Research for this specific use included RCTs and long-term Observational Registries, which primarily examined the Calcitriol agent in patient populations facing chronic mineral regulation challenges. This included conditions such as Chronic Kidney Disease (CKD) and Chronic Hypoparathyroidism. Researchers monitored outcomes related to serum calcium and Parathyroid Hormone (PTH) Levels to explore temporary physiological imbalance.

Despite the established research base for the Calcitriol component, evidence is limited regarding the added role of the Zinc component in regulating mineral imbalances in these highly specialized conditions. The research focuses heavily on biochemical endpoints, meaning patient-reported outcomes over sustained periods are not fully established.

Key Studies & References

  1. Overview of Calcium - Dietary Reference Intakes for Calcium and Vitamin D
  2. Calcitriol - StatPearls - NCBI Bookshelf - NIH (Used for CKD indications and patient populations)

Frequently Asked Questions (FAQ)

Common questions about Quical-XT (FAQ)


Q: How quickly should I start to notice the intended effect of Quical-XT?

Official information indicates that the Calcitriol component is rapidly absorbed, with peak concentrations typically measured within a few hours of an oral dose. However, the medicine's main long-term effect is achieved slowly over time. The official regimen requires a structured titration schedule, where the dose is adjusted over weeks based on required laboratory tests.


Q: Does Quical-XT need to build up in my system to work properly?

Yes, to some extent. The Calcitriol component requires multiple doses to reach a consistent level in the body, known as a steady state, which typically occurs after about seven days. The official dosing schedule is structured to slowly titrate the dose—meaning adjust it over time—to help reach a level that is appropriate for chronic mineral management, as determined by monitoring.


Q: How long does Quical-XT stay in the body after the last use?

The elimination half-life of the Calcitriol component in serum is approximately 5 to 8 hours in healthy subjects. While the medicine is quickly processed, its pharmacological action, or the time it actively works in the body, may continue for a longer period, sometimes lasting up to 3 to 5 days after the final dose.


Q: Is it safe to drink alcohol while using Quical-XT?

Official regulatory documents do not typically list alcohol as a specific substance to be avoided with this medicine. However, regulatory caution focuses on avoiding abrupt changes in intake of dietary calcium, vitamin D, and phosphate-containing foods or beverages, as these can affect the medicine's effectiveness and safety profile.


Q: Can Quical-XT interact with over-the-counter pain relievers like ibuprofen?

The official product information mandates a separation of 2 to 4 hours between this medicine and several other types of prescription medicines. This separation is required because the Calcium and Zinc components can reduce the absorption of other products through a process called chelation. This same principle of separation may apply to certain over-the-counter products, including some pain relievers, even if they are not explicitly listed.


Q: Is Quical-XT safe to use during pregnancy?

Regulatory documents classify the medicine's use during pregnancy as Category C. This classification indicates that animal reproduction studies have shown an adverse effect on the fetus. Official information notes that there is a lack of adequate and well-controlled studies in human pregnancies.


Q: What is the information about using Quical-XT while breastfeeding?

Official regulatory information notes that the Calcitriol component is transferred into breast milk, although usually at low levels. Due to the potential for adverse effects in the infant from this transfer, official information indicates that a decision must be made regarding the continuance of nursing or the drug.


Q: Does Quical-XT have a known risk of dependence?

The official safety profile for Quical-XT does not list drug dependence or addictive properties as a recognized risk or adverse reaction. The primary safety concerns documented in regulatory materials relate strictly to mineral imbalance, specifically the risk of Hypercalcemia (elevated blood calcium).


Q: Does Quical-XT affect sleep patterns?

While direct effects on sleep are not listed, official safety documents indicate that symptoms like tiredness (fatigue) and dizziness may occur as signs of the medicine's most common adverse reaction, Hypercalcemia (elevated blood calcium). Patients are advised to review the official safety information if these symptoms occur.


Q: Is it normal to feel tired or dizzy after starting Quical-XT?

Symptoms like tiredness and dizziness are documented as potential signs of the most common adverse reaction, Hypercalcemia (elevated blood calcium). The full official safety information details a complete list of documented effects.


Q: Is it required to have regular blood tests while taking Quical-XT?

Yes. The official treatment guidelines state that periodic monitoring is mandatory. This includes measuring serum calcium and phosphorus levels. These laboratory test results are critical, as they guide all procedural decisions regarding dosage adjustments.


Q: Does Quical-XT have any restrictions for driving or operating machinery?

The primary adverse effect, Hypercalcemia, may cause symptoms such as dizziness and drowsiness. The official warning advises caution regarding activities that require full mental alertness, such as driving or operating heavy machinery.


Q: Do I need a prescription to get Quical-XT?

Yes, the inclusion of the component Calcitriol means that this medicine is typically classified as a prescription-required product by regulatory bodies. This differentiates it from general over-the-counter mineral supplements.


Q: What about using Quical-XT if I have kidney issues?

Use of this medicine is restricted and requires extreme caution in patients with renal impairment (kidney issues). The official prescribing information strictly mandates frequent monitoring of serum calcium and phosphate levels to manage the heightened risk of serious calcification.


Q: What are the inactive ingredients in Quical-XT?

The complete list of inactive ingredients (also called excipients) used in the product's capsule or tablet formulation is detailed in the official regulatory documentation. This information can typically be found under the 'Description,' 'Components,' or 'Ingredients' section of the medicine's label.


Q: Why do some people stop using Quical-XT?

The most common official reason documented for requiring discontinuation or temporary interruption of treatment is the development of Hypercalcemia (elevated blood calcium). This is the most clinically significant adverse reaction listed in regulatory documents.


Q: Where can I find the official patient information leaflet for Quical-XT?

The official regulatory agencies publish the complete Patient Information Leaflet (PIL). This document can be found by searching the government databases of authoritative agencies such as the NIH DailyMed or the MHRA/EMA.


Q: Does the time of day matter when taking Quical-XT?

The official dosing regimen specifies taking the medicine once daily. Regulatory documents do not typically mandate a specific time of day, such as morning or evening. However, consistency in the dosing time is generally advised, along with ensuring the required administration separation from certain other products.


Q: Can teenagers or children use Quical-XT?

Official documents state that the safety and effectiveness of the medicine are often not established for all specific pediatric age groups or indications. Due to the potency of the components, use in children and teenagers is subject to specific prescribing guidance as outlined in the official label.

How should Quical-XT be stored and disposed of?

How to Store and Dispose of Quical-XT

The storage of Quical-XT is governed by official requirements to protect the product's stability, particularly that of the Calcitriol component.

Storage Requirements

Condition Requirement
Temperature Store at room temperature, away from excess heat.
Protection Must be protected from light and excess moisture.
Container Keep in the original container, tightly closed.

Child Safety and Disposal

Quical-XT must be kept in a safe location, out of the sight and reach of children and pets, and safety caps must always be locked.

Unused or expired product must be properly discarded and should not be poured down a drain or flushed into a toilet, as per regulatory mandates. Patients are advised to consult a pharmacist or local take-back program for authorized disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Quical-XT found in:

A-Z Index: